BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 33768546)

  • 21. Effects of Wuzhi Capsules on Blood Concentration of Tacrolimus in Renal Transplant Recipients.
    Yan L; Yang ZQ; Shi YY; Ren J; Yang CL; Wan ZL; Bai YJ; Luo LM; Wang LL; Li Y
    Ann Transplant; 2019 Nov; 24():594-604. PubMed ID: 31712547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients.
    Teng F; Zhang W; Wang W; Chen J; Liu S; Li M; Li L; Guo W; Wei H
    Biopharm Drug Dispos; 2022 Apr; 43(2):76-85. PubMed ID: 35220592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
    Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
    Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
    Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
    J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients.
    Zhu L; Yang J; Zhang Y; Jing Y; Zhang Y; Li G
    Xenobiotica; 2015; 45(9):840-6. PubMed ID: 25869250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA; Lacchini R; Romao EA; Moysés-Neto M; Coelho EB
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
    Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
    Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule.
    Chen X; Wang DD; Xu H; Li ZP
    Xenobiotica; 2020 May; 50(5):606-613. PubMed ID: 31530218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tacrolimus Population Pharmacokinetics and Multiple CYP3A5 Genotypes in Black and White Renal Transplant Recipients.
    Campagne O; Mager DE; Brazeau D; Venuto RC; Tornatore KM
    J Clin Pharmacol; 2018 Sep; 58(9):1184-1195. PubMed ID: 29775201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus population pharmacokinetic models according to CYP3A5/CYP3A4/POR genotypes in Chinese Han renal transplant patients.
    Zhu W; Xue L; Peng H; Duan Z; Zheng X; Cao D; Wen J; Wei X
    Pharmacogenomics; 2018 Aug; 19(13):1013-1025. PubMed ID: 30040022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
    Wang CB; Zhang YJ; Zhao MM; Zhao L
    Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
    Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
    Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.
    Chen P; Dai R; She Y; Fu Q; Huang M; Chen X; Wang C
    Clin Transplant; 2022 Dec; 36(12):e14807. PubMed ID: 36057787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.